Primer Capital

Nelo is a Mexico City-based company that specializes in developing a mobile application for financial transactions. Founded on April 8, 2019, Nelo offers a digital payment management platform that enables users to track their financial transactions effectively. The platform allows individuals to send and request money while providing a free virtual card with no charges for account opening. This functionality facilitates real-time payment and balance tracking, empowering users to manage their funds in an affordable and secure manner.

MatriSys Bioscience, Inc. is a clinical stage biopharmaceutical company based in La Jolla, California, focused on developing and commercializing microbiome therapies for the dermatology and skin care markets. Founded in 2015, the company is advancing its lead product, MSB-01, a topical antimicrobial live biotherapeutic designed to restore the balance of skin bacteria in patients with atopic dermatitis. This innovative treatment aims to enhance host defense by reintroducing beneficial bacteria that are often deficient in these patients. Additionally, MatriSys produces cosmetic ingredients derived from its proprietary bacterial strains, which are formulated to address various skin concerns such as scaling, flaking, and signs of aging. The company's products are marketed through prescription dermatology channels as well as skin care and cosmetic routes, and its therapies are currently undergoing Phase I/II clinical trials.

Botkin.AI is a healthcare technology company based in Moscow, founded in 2015, specializing in medical image processing and analysis through artificial intelligence. The company's platform utilizes deep machine learning to analyze radiograms and assess the risk of tumors, enhancing the diagnostic capabilities of radiologists. By enabling the accurate early detection of oncological diseases, particularly lung cancer, Botkin.AI facilitates a faster processing of clinical data while maintaining high-quality medical conclusions. This innovative approach aims to improve the overall efficiency and effectiveness of healthcare providers in diagnosing critical conditions.

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, focused on developing small molecules aimed at restoring neuronal health and halting neurodegeneration. The company's lead product candidate, ATH-1017, is a small molecule designed to penetrate the blood-brain barrier and acts as a hepatocyte growth factor/MET activator, currently undergoing various clinical trials for treating Alzheimer’s and Parkinson’s diseases. In addition to ATH-1017, Athira is developing several other candidates, including ATH-1019 for depression and ATH-1018 for peripheral neuropathy, which are in the preclinical stage. Founded in 2011 and initially known as M3 Biotechnology, Athira Pharma changed its name in April 2019 to reflect its mission of advancing innovative therapies to improve the lives of individuals affected by brain disorders.

MatriSys Bioscience, Inc. is a clinical stage biopharmaceutical company based in La Jolla, California, focused on developing and commercializing microbiome therapies for the dermatology and skin care markets. Founded in 2015, the company is advancing its lead product, MSB-01, a topical antimicrobial live biotherapeutic designed to restore the balance of skin bacteria in patients with atopic dermatitis. This innovative treatment aims to enhance host defense by reintroducing beneficial bacteria that are often deficient in these patients. Additionally, MatriSys produces cosmetic ingredients derived from its proprietary bacterial strains, which are formulated to address various skin concerns such as scaling, flaking, and signs of aging. The company's products are marketed through prescription dermatology channels as well as skin care and cosmetic routes, and its therapies are currently undergoing Phase I/II clinical trials.

Acticor Biotech SAS is a clinical-stage biopharmaceutical company based in Paris, France, founded in 2013. The company specializes in developing innovative therapeutic monoclonal antibodies aimed at treating acute thrombotic diseases, particularly focusing on acute ischemic stroke. Its lead product, Glenzocimab, is a humanized antibody designed to address the critical need for new therapeutic options in the management of stroke, a condition that affects millions globally each year and leads to significant mortality and disability. Currently, existing treatments for ischemic stroke have limited efficacy and reach, highlighting the urgent demand for more effective solutions. Acticor Biotech is dedicated to advancing its novel therapies to meet this pressing medical need.

GemoPharm is a biotechnology company focused on developing innovative therapies for challenging medical conditions. Its lead asset is a monoclonal antibody targeting CD71 within the tumor microenvironment, designed to minimize toxicities commonly associated with traditional therapies. The company has successfully generated in vivo proof-of-concept data that demonstrate substantial efficacy and validate the mechanism of action for its lead candidate. Additionally, pilot toxicology studies have been completed without any signs of significant toxicity. GemoPharm aims to address the significant unmet medical needs for effective treatments of relapsed or refractory primary and secondary central nervous system lymphomas and intraocular lymphomas. The company’s research also extends to developing humanized antibodies with strong antitumor activity and minimal toxicity, leveraging cellular and biomolecular processes to enhance patient outcomes in the fight against infections.

MT-Medicals developed a highly specific inhibitor of cytochrome P450 enzymes that demonstrate high conservation, which greatly reduces the probability of tuberculosis bacterial resistance to the new treatment. Its use significantly optimizes the existing combined treatment regimens for resistant forms of tuberculosis and supports the individualization of such treatment. MT-Medicals is based in Hefei City, Anhui Province, China.

Bendit is a medical company specializing in the development and manufacturing of innovative catheters that utilize a unique bending technology. This technology provides enhanced steering capabilities in both micro diameter and conventional catheter wires and tubes. The company focuses on creating microcatheter devices that enable precise navigation within the body, allowing healthcare professionals to access targeted sites with minimal tools and reduced risks. Bendit's products are designed to improve the success rates of medical procedures by offering peripheral and visceral microcatheters that can be shaped and directed as needed. The company is a joint venture formed by three experienced groups in production, quality and regulation, and medical development, bringing together expertise to advance catheter technology.

Botkin.AI is a healthcare technology company based in Moscow, founded in 2015, specializing in medical image processing and analysis through artificial intelligence. The company's platform utilizes deep machine learning to analyze radiograms and assess the risk of tumors, enhancing the diagnostic capabilities of radiologists. By enabling the accurate early detection of oncological diseases, particularly lung cancer, Botkin.AI facilitates a faster processing of clinical data while maintaining high-quality medical conclusions. This innovative approach aims to improve the overall efficiency and effectiveness of healthcare providers in diagnosing critical conditions.

Data MATRIX Ltd. is a data management and statistical services company based in Saint Petersburg, Russia, established in 2014. It specializes in providing cloud-based solutions for clinical data management, including its proprietary Matrix EDC platform, which facilitates electronic, paper-based, and hybrid studies. The company also offers Matrix IWRS for patient randomization and supply management, as well as Matrix CTMS for overseeing clinical trials. Data MATRIX supports the entire clinical research process by providing services such as data work planning, case report form design, and database customization. It employs both automated and manual methods for data verification while ensuring compliance with international and local regulations regarding personal data processing. Additionally, the company offers ePRO solutions aimed at improving the quality of patient-reported outcomes. With a focus on innovation, Data MATRIX integrates artificial intelligence tools to enhance data management, enabling biotechnology firms to streamline their clinical trial operations and reporting functions.

MiNDERA Corporation specializes in the development of non-invasive molecular testing devices aimed at diagnosing skin cancer and other skin diseases. The company has created a micro-needle array patch that allows for pain-free and minimally invasive extraction of biomarkers, such as RNA, DNA, and proteins, from the skin without the need for traditional biopsies. Additionally, MiNDERA develops specialized patches for whole transcriptome extraction and skin microbiome extraction, which are designed for research applications. Founded in 2013, MiNDERA is headquartered in Palo Alto, California.

FK Laboratoriz has developed a drug which is a new structure of a highly specific direct thrombin inhibitor. Its expected pharmacological effects correspond to those stipulated by international standards and enable the product to compete with other medicinal products available at the EEU market. The drug was developed with the use of a combination of computer-based simulation and chemosynthesis, which are modern and recognized methods applied in the pharmaceutical industry.

Solo is a service for personalized anticancer therapy selection.